Figure 5.
Rbms3 loss cooperates with EGFRL858R to accelerate malignant lung adenocarcinoma. A–C, Images of harvested mouse lung sections following necropsy analyses stained with H&E 11 weeks after initiation with 1×105 pfu lenti-CRE, followed by continuous administration of doxycycline chow to induce EGFRL858R expression. CRISPR/CAS9-mediated genome editing was used in B and C to edit Rbms3 in vivo. Genotype of each experimental group was: A, sgRbms3-CRE virus in SPC::CRE-ERT2/+; Rosa26CAGs-LSL-rTTa3; EGFRL858R (SRE) mice. B, sgNT-CRE virus in or SPC::CRE-ERT2/+; Rosa26CAGs-LSL-rTTa3; EGFRL858R; H11LSL-CAS9/+ (SREC) mice. C, sgRbms3-CRE virus in SREC mice. Scale bar, 1,000 μm. D, Quantification of tumor burden from genotypes in B compared with C. N = 5 mice per group. The mean is graphed. Error bars, SEM. Statistical analysis was conducted using a paired t test; ****, P < 0.0001. E–H, Representative images of IHC on FFPE lung tissue sections from SREC mice initiated with either sgNT- or sgRbms3-CRE and stained with pEGFR (pY1068) or pERK (pT202; Y204) shown at ×20 magnification. Scale bar, 50 μm.